|
1
|
Abilleira S, Bevan S and Markus HS: The
role of genetic variants of matrix metalloproteinases in coronary
and carotid atherosclerosis. J Med Genet. 43:897–901. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chen QJ, Lu L, Peng WH, Hu J, Yan XX, Wang
LJ, Zhang Q, Zhang RY and Shen WF: Polymorphisms of MMP-3 and
TIMP-4 genes affect angiographic coronary plaque progression in
non-diabetic and type 2 diabetic patients. Clin Chim Acta.
405:97–103. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ye S, Gale CR and Martyn CN: Variation in
the matrix metalloproteinase-1 gene and risk of coronary heart
disease. Eur Heart J. 24:1668–1671. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhang B, Ye S, Herrmann SM, Eriksson P, de
Maat M, Evans A, Arveiler D, Luc G, Cambien F, Hamsten A, et al:
Functional polymorphism in the regulatory region of gelatinase B
gene in relation to severity of coronary atherosclerosis.
Circulation. 99:1788–1794. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Beyzade S, Zhang S, Wong YK, Day IN,
Eriksson P and Ye S: Influences of matrix metalloproteinase-3 gene
variation on extent of coronary atherosclerosis and risk of
myocardial infarction. J Am Coll Cardiol. 41:2130–2137. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rauramaa R, Väisänen SB, Luong LA,
Schmidt-Trücksäss A, Penttilä IM, Bouchard C, Töyry J and Humphries
SE: Stromelysin-1 and interleukin-6 gene promoter polymorphisms are
determinants of asymptomatic carotid artery atherosclerosis.
Arterioscler Thromb Vasc Biol. 20:2657–2662. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Liu PY, Li YH, Chan SH, Lin LJ, Wu HL, Shi
GY and Chen JH: Genotype-phenotype association of matrix
metalloproteinase-3 polymorphism and its synergistic effect with
smoking on the occurrence of acute coronary syndrome. Am J Cardiol.
98:1012–1017. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Johnson C and Galis ZS: Matrix
metalloproteinase-2 and −9 differentially regulate smooth muscle
cell migration and cell-mediated collagen organization.
Arterioscler Thromb Vasc Biol. 24:54–60. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sambrook J and Russell DW: Purification of
nucleic acids by extraction with phenol: chloroform. CSH Protoc.
2006(pii): pdb.prot4455. 2006.
|
|
10
|
Xie X and Ott J: Testing linkage
disequilibrium between a disease gene and marker loci. Am J Hum
Genet. 53:1107–1113. 1993.PubMed/NCBI
|
|
11
|
Hoppmann P, Koch W, Schömig A and Kastrati
A: The 5A/6A polymorphism of the stromelysin-1 gene and restenosis
after percutaneous coronary interventions. Eur Heart J. 25:335–341.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Koch W, de Waha A, Hoppmann P, Schömig A
and Kastrati A: Haplotypes and 5A/6A polymorphism of the matrix
metalloproteinase-3 gene in coronary disease: Case-control study
and a meta-analysis. Atherosclerosis. 208:171–176. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ye S, Watts GF, Mandalia S, Humphries SE
and Henney AM: Preliminary report: Genetic variation in the human
stromelysin promoter is associated with progression of coronary
atherosclerosis. Br Heart J. 73:209–215. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Humphries S, Bauters C, Meirhaeghe A,
Luong L, Bertrand M and Amouyel P: The 5A6A polymorphism in the
promoter of the stromelysin-1 (MMP3) gene as a risk factor for
restenosis. Eur Heart J. 23:721–725. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
de Maat MP, Jukema JW, Ye S, Zwinderman
AH, Moghaddam PH, Beekman M, Kastelein JJ, van Boven AJ, Bruschke
AV, Humphries SE, et al: Effect of the stromelysin-1 promoter on
efficacy of pravastatin in coronary atherosclerosis and restenosis.
Am J Cardiol. 83:852–856. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Humphries SE, Luong LA, Talmud PJ, Frick
MH, Kesäniemi YA, Pasternack A, Taskinen MR and Syvänne M: The
5A/6A polymorphism in the promoter of the stromelysin-1 (MMP-3)
gene predicts progression of angiographically determined coronary
artery disease in men in the LOCAT gemfibrozil study. Lopid
Coronary Angiography Trial. Atherosclerosis. 139:49–56. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hirashiki A, Yamada Y, Murase Y, Suzuki Y,
Kataoka H, Morimoto Y, Tajika T, Murohara T and Yokota M:
Association of gene polymorphisms with coronary artery disease in
low- or high-risk subjects defined by conventional risk factors. J
Am Coll Cardiol. 42:1429–1437. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Schwarz A, Haberbosch W, Tillmanns H and
Gardemann A: The stromelysin-1 5A/6A promoter polymorphism is a
disease marker for the extent of coronary heart disease. Dis
Markers. 18:121–128. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Blankenberg S, Rupprecht HJ, Poirier O,
Bickel C, Smieja M, Hafner G, Meyer J, Cambien F and Tiret L:
AtheroGene Investigators: Plasma concentrations and genetic
variation of matrix metalloproteinase 9 and prognosis of patients
with cardiovascular disease. Circulation. 107:1579–1585. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Johnson GC, Esposito L, Barratt BJ, Smith
AN, Heward J, Di Genova G, Ueda H, Cordell HJ, Eaves IA, Dudbridge
F, et al: Haplotype tagging for the identification of common
disease genes. Nat Genet. 29:233–237. 2001. View Article : Google Scholar : PubMed/NCBI
|
